Request Trial
shutterstock_1169047330_markvanscyoc-1
markvanscyoc / shutterstock.com
22 March 2021Alex Baldwin

Reviewing the inter partes review

The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Pharmascience v Janssen: Canada court updates methods of medical treatment protection
23 July 2026   Canada has firmly slammed the door on patenting methods of medical treatment—but the battle over what counts as a "medical method" is only just beginning. Scott MacKendrick of ROBIC examines a landmark decision that leaves the door ajar for future litigation over complex drug-dosing regimens.
Regulation & Industry
UK Prime Minister axes science ministry in govt shakeup
22 July 2026   Plans to merge the UK’s standalone science ministry into an expanded business department, coupled with the departure of the Science Minister, mark a change in the country’s approach to science and innovation.
Biotech
Masimo keeps $634m smartwatch award and moves to appeal
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.


Editor's picks

Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026

Editor's picks

Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Regulation & Industry
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Regulation & Industry
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

UK Prime Minister axes science ministry in govt shakeup
Masimo keeps $634m smartwatch award and moves to appeal
Arbutus takes Comirnaty LNP patent fight to Canada and UPC
Why is 2026 already a record year for M&A activity?
Illumina ordered to recall products after German patent ruling
Goodwin launches San Diego office with senior life sciences hire
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
UK-Switzerland strike trade deal with first-of-its-kind pharma rules